Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA2 | Q9HCG7 | 19/20 | 0.55 |
| ▸ | GBA1 | P04062 | 8/20 | 0.55 |
| ▸ | GAA | P10253 | 6/20 | 0.55 |
| ▸ | UGCG | Q16739 | 4/20 | 0.55 |
| ▸ | MGAM | O43451 | 2/20 | 0.55 |
| ▸ | SI | P14410 | 2/20 | 0.55 |
| ▸ | AGL | P35573 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2790138 | 0.87 | GAA (0.53) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL3017615 | 0.86 | GBA2 (0.56) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL4433960 | 0.84 | GAA (0.50) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL3021725 | 0.81 | GAA (0.56) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL14319851 | 0.76 | GBA2 (0.59) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL3381825 | 0.75 | GBA2 (0.57) | GBA2GBA1GAAUGCGMGAM | |
| SCHEMBL2354118 | 0.72 | GBA2 (0.48) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL23503067 | 0.71 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20576705 | 0.71 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM | |
| Miglustat SCHEMBL20577242 | 0.71 | GBA2 (1.00) | GBA2GBA1GAAUGCGMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061922-B9 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | UNITED THERAPEUTICS CORP (US) | 2007-03-07 | — | — | EP | claimed |
| EP-1714676-A2 | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | G.D. Searle LLC. (US) | 2006-10-25 | — | — | EP | claimed |
| EP-1061922-B1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | SEARLE LLC (US) | 2006-06-28 | — | — | EP | claimed |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | PHARMACIA CORPORATION | 2005-06-02 | — | — | US | claimed |
| US-6689759-B1 | COMBINED WITH NUCLEOSIDE AND/OR NUCLEOTIDE ANTIVIRAL AGENTS AND IMMUNOSTIMULANTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | claimed |
| EP-1030839-B1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | SEARLE & CO (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030100532-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | UNITED THERAPEUTICS CORPORATION | 2003-05-29 | — | — | US | claimed |
| EP-1261339-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | Pharmacia Corporation (US) | 2002-12-04 | — | — | EP | claimed |
| JP-2002502875-A | — | — | 2002-01-29 | — | — | JP | claimed |
| WO-2001060366-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | PHARMACIA CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| US-6225325-B1 | ADMINISTERING N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL OR GALACTITOL FOR PROPHYLAXIS, THERAPY, REDUCING, OR REVERSING MULTIDRUG RESISTANCE IN PATIENT UNDERGOING THERAPY WITH CHEMOTHERAPEUTIC AGENT | G.D. SEARLE & COMPANY | 2001-05-01 | — | — | US | claimed |
| EP-1061922-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 2000-12-27 | — | — | EP | claimed |
| EP-1007058-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. Searle & Co. (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1999040916-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | claimed |
| WO-1998035685-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE AND CO. (US) | 1998-08-20 | — | — | WO | claimed |
| US-8703744-B2 | Cholesterol level lowering liposomes | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-04-22 | — | — | US | disclosed |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | THE CHANCELLORS, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-1030839-A1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | G.D. SEARLE & CO. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999040916-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999024401-A1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | G.D. SEARLE & CO. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100532-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | HAVCR2, DERA, GALE | GBA2 433/4885GBA1 232/4885GAA 507/4885 |
| US-20050119310-A1 | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections | HAVCR2, DERA, IMPDH1 | GBA2 581/4885GBA1 233/4885GAA 579/4885 |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | EIF2AK2, ZC3HAV1, HAVCR2 | GBA2 1764/4885GBA1 654/4885GAA 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.